Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2025-04-28 Delisting Announcement
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于公司股票交易被实行退市风险警示暨停牌的公告
Delisting Announcement Classification · 100% confidence The document is an official announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the implementation of a delisting risk warning and trading suspension of its stock. It references the company's 2024 annual report audited results but does not contain the report itself or detailed financial statements. The document explains the reasons for the delisting risk warning, the regulatory basis under Shenzhen Stock Exchange rules, and the company's plans to address the situation. It is a formal notice about the stock's trading status and risk warning rather than a full financial report or audit report. Given the content and the nature of the announcement, this fits the definition of a Delisting Announcement (DLST). The document length is short and focused on the delisting risk warning and trading suspension, consistent with a DLST filing rather than a full annual report or audit report.
2025-04-28 Chinese
年度关联方资金占用专项审计报告
Regulatory Filings
2025-04-28 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the 10th Board of Directors meeting of Jiangsu Sihuan Bio Co., Ltd. It details the approval of various reports and proposals including the 2024 Annual Report, Board Work Report, Financial Report, Profit Distribution Plan, and other governance matters. The document is relatively short (2304 characters) and repeatedly states that the full reports are disclosed elsewhere (on cninfo.com.cn and other media). It is a formal announcement of board meeting resolutions rather than the full annual report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it does not contain the full financial statements or detailed report content but announces the board's decisions and references the full reports published elsewhere.
2025-04-28 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2024 Annual Report Summary" of 江苏四环生物股份有限公司, indicating it is a summary derived from the full annual report. It contains detailed financial data for the year 2024, including total assets, net profit, revenue, earnings per share, and quarterly financial data. It also discusses company business segments, industry context, shareholder information, and significant events related to shareholding changes. The document length is over 5,000 characters and contains substantive financial and operational data, not just an announcement or a certification. Therefore, it fits the definition of an Annual Report (10-K) rather than a report publication announcement or regulatory filing. The presence of detailed financial statements and business overview confirms this classification with high confidence. FY 2024
2025-04-28 Chinese
江苏四环生物股份有限公司2024年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度董事会工作报告" which translates to "2024 Annual Board of Directors Work Report". It details the board's activities, meetings, resolutions, governance, internal control evaluations, and shareholder relations for the year 2024. It includes specifics about board meetings, committee work, and governance practices but does not contain full financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). The content focuses on the board's work and governance rather than financial results or audit opinions. Therefore, the document fits best under the category of Board/Management Information (MANG), which covers announcements about board activities and management information.
2025-04-28 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2024 年度内部控制评价报告' which translates to '2024 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including detailed standards for identifying internal control deficiencies, both financial and non-financial. The content focuses on internal control evaluation, defect recognition, and remediation status, which aligns with audit-related information rather than a full annual report or other categories. The document length is 3278 characters, which is relatively short but contains substantive content on internal control evaluation rather than just an announcement. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. FY 2024
2025-04-28 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.